```
d his

     (FILE 'HOME' ENTERED AT 11:55:41 ON 22 JUL 2005)

     FILE 'USPATFULL' ENTERED AT 11:55:50 ON 22 JUL 2005
L1           10 S (LYSOSTAPHIN AND PENICILLIN)/CLM

=> d bib,kwic 1-10

L1   ANSWER 1 OF 10  USPATFULL on STN
AN     2004:314527  USPATFULL
TI     Method for determining the presence of bacteria resistant to cell lysing
       antibiotics
IN     Squirrell, David James, Salisbury, UNITED KINGDOM
       Leslie, Rachel Louise, Salisbury, UNITED KINGDOM
       Brown, Kevin J, Salisbury, UNITED KINGDOM
PI     US 2004248199      A1   20041209
AI     US 2004-490229     A1   20040319 (10)
       WO 2002-GB3990          20020902
PRAI   GB 2001-22790       20010921
DT     Utility
FS     APPLICATION
LREP   JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET,
       ATLANTA, GA, 30309
CLMN   Number of Claims: 23
ECL    Exemplary Claim: 1
DRWN   3 Drawing Page(s)
LN.CNT 380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM    What is claimed is:
       6. The method of claim 5, wherein the agent capable of causing cell
       lysis is lysostaphin.

       18. The test kit of claim 14, wherein the one or more cell lysing agents
       comprise lysostaphin.

       21. The method of claim 1, wherein the cell lysing antibiotic is a
       penicillin.

       23. The test kit of claim 14, wherein the cell lysing antibiotic is a
       penicillin.


L1   ANSWER 2 OF 10  USPATFULL on STN
AN     2004:100763  USPATFULL
TI     Bandage composition containing phage associated lytic enzymes useful for
       treating dermatological infections
IN     Fischetti, Vincent, West Hempstead, NY, UNITED STATES
       Loomis, Lawrence, Columbia, MD, UNITED STATES
PI     US 2004076624      A1   20040422
AI     US 2003-465889     A1   20030620 (10)
RLI    Continuation of Ser. No. US 2001-932460, filed on 20 Aug 2001, PENDING
       Continuation of Ser. No. US 2000-671882, filed on 28 Sep 2000, GRANTED,
       Pat. No. US 6277399 Continuation-in-part of Ser. No. US 2000-497495,
       filed on 18 Apr 2000, GRANTED, Pat. No. US 6238661 Continuation of Ser.
       No. US 1999-395636, filed on 14 Sep 1999, GRANTED, Pat. No. US 6056954
       Continuation-in-part of Ser. No. US 1997-962523, filed on 31 Oct 1997,
       GRANTED, Pat. No. US 5997862
DT     Utility
FS     APPLICATION
LREP   Jonathan E. Grant, 2107 Hounds Run Place, Silver Spring, MD, 20906
CLMN   Number of Claims: 15
ECL    Exemplary Claim: 1
DRWN   1 Drawing Page(s)
LN.CNT 916
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM    What is claimed is:
       11) The method according to claim 1, wherein the composition further
```

comprises at least one complementary agent which potentiates the bactericidal activity of the at least one lytic enzyme, said complementary agent being selected from the group consisting of **penicillin**, synthetic **penicillins** bacitracin, methicillin, cephalosporin, polymyxin, cefaclor. Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefmetazole, cefonioid, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil,. . .

12) The method according to claim 1, wherein the composition further comprises **lysostaphin** for the treatment of any Staphylococcus aureus bacteria.

L1 ANSWER 3 OF 10 USPATFULL on STN
AN 2003:283088 USPATFULL
TI Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
IN Climo, Michael, Richmond, VA, UNITED STATES
Murphy, Ellen, Bronx, NY, UNITED STATES
Archer, Gordon, Richmond, VA, UNITED STATES
PI US 2003199432 A1 20031023
AI US 2003-414566 A1 20030416 (10)
RLI Division of Ser. No. US 1999-263776, filed on 5 Mar 1999, GRANTED, Pat. No. US 6569830
DT Utility
FS APPLICATION
LREP Supervisor, Patent Prosecution Services, PIPER RUDNICK LLP, 1200 Nineteenth Street, N.W., Washington, DC, 20036-2412
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:

2. The method of claim 1, wherein said peptidoglycan active agent is **lysostaphin**

8. The method of claim 7, wherein said β-lactam is selected from the group consisting of a **penicillin**, a cephalosporin and a carbapenem.

9. The method of claim 8, wherein said β-lactam is a **penicillin**.

13. The composition of claim 12, wherein said anti-staphylococcal peptidoglycan active agent is **lysostaphin**.

16. The composition of claim 15, wherein said β-lactam is selected from the group consisting of a **penicillin**, a cepalosporin and a carbapenem.

17. The composition of claim 16, wherein said β-lactam is a **penicillin**.

L1 ANSWER 4 OF 10 USPATFULL on STN
AN 2003:143040 USPATFULL
TI Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
IN Climo, Michael, Richmond, VA, United States
Murphy, Ellen, Bronx, NY, United States
Archer, Gordon, Richmond, VA, United States
PA Ambi, Inc., Purchase, NY, United States (U.S. corporation)
PI US 6569830 B1 20030527
AI US 1999-263776 19990305 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Borin, Michael

LREP Piper Rudnick LLP, Kelber, Steven B.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
1. A pharmaceutical composition in dosage form for treating a staphylococcal infection in a human subject, said composition comprising: **lysostaphin** in an amount of from 15 to 150 mg/kg body weight of the human subject; and a β-lactam antibiotic in. . . human subject for a period of time sufficient to eradicate said infection, suppresses formation of staphylococcal strains resistant to said **lysostaphin**, said cell-wall active antibiotic and said composition, and wherein said amount of **lysostaphin** is an amount effective in treating, in a human, a staphylococcal infection that is not **lysostaphin**-resistant and wherein said amount of the cell-wall active antibiotic is an amount effective in treating, in a human, a staphylococcal. . .
2. The composition of claim 1, wherein the β-lactam is selected from the group consisting of a **penicillin**, a cepalosporin and a carbapenem.

3. The composition of claim 2, wherein the β-lactam is **penicillin**.

L1 ANSWER 5 OF 10 USPATFULL on STN
AN 2002:329457 USPATFULL
TI Use of bacterial phage associated lysing enzymes for treating various illnesses
IN Loomis, Lawrence, Columbia, MD, UNITED STATES
Fischetti, Vincent, West Hempstead, NY, UNITED STATES
PI US 2002187136 A1 20021212
AI US 2001-844435 A1 20010430 (9)
RLI Continuation-in-part of Ser. No. US 2000-560650, filed on 28 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2001-752732, filed on 3 Jan 2001, PENDING
DT Utility
FS APPLICATION
LREP HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006
CLMN Number of Claims: 151
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2043
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
112. The method according to claim 103, wherein the composition further comprises at least one complementary agent which potentiates the bactericidal activity of the lytic enzyme, said complementary agent being selected from the group consisting of **penicillin**, synthetic **penicillins** bacitracin, methicillin, cephalosporin, polymyxin, cefaclor. Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefinetazole, cefonioid, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil,. . .
113. The method according to claim 103, wherein the composition further comprises **lysostaphin** for the treatment of any Staphylococcus aureus bacteria.

. . . agent which potentiates the bactericidal activity of the lysine enzyme, said complementary agent being selected from the group consisting of **penicillin**, synthetic **penicillins** bacitracin, methicillin, cephalosporin, polymyxin, cefaclor. Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefinetazole, cefonioid, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil,. . .

L1 ANSWER 6 OF 10 USPATFULL on STN
AN 2001:93093 USPATFULL
TI Bacterial phage associated lysing enzymes for treating dermatological infections
IN Fischetti, Vincent, 448 Joan Ct., West Hempstead, NY, United States 11552
Loomis, Lawrence, 11374 Buckelberry Path, Columbia, MD, United States 21044
PI US 6248324 B1 20010619
AI US 2000-671879 20000928 (9)
RLI Continuation of Ser. No. US 2000-395636, filed on 14 Sep 2000, now patented, Pat. No. US 6056954 Continuation-in-part of Ser. No. US 2000-497495, filed on 18 Apr 2000 Continuation-in-part of Ser. No. US 1997-962523, filed on 31 Oct 1997, now patented, Pat. No. US 5997862
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bawa, Raj
LREP Grant, Jonathan E.Grant Patent Services
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 904
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
. . . potentiates the bactericidal activity of the at least one lytic enzyme, said complementary agent selected from the group consisting of **penicillin**, synthetic **penicillins** bacitracin, methicillin, cephalosporin, polymyxin, cefaclor, Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefmetazole, cefonioid, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil,. . .
11. The method according to claim 1, wherein the therapeutic agent further comprises **lysostaphin** for the treatment of Staphylococcus aureus.

L1 ANSWER 7 OF 10 USPATFULL on STN
AN 2000:53739 USPATFULL
TI Topical treatment of streptococcal infections
IN Fischetti, Vincent, 488 Joan Ct., West Hempstead, NY, United States 11552
Loomis, Lawrence, 11374 Buckleberry Path, Columbia, MD, United States 21044
PI US 6056955 20000502
AI US 1999-395637 19990914 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Bawa, Raj
LREP Grant, Grant Patent Services, Jonathan
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 634
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
. . . agent which potentiates the bactericidal activity of the lysine enzyme, said complementary agent being selected from the group consisting of **penicillin**, synthetic **penicillins** bacitracin, methicillin, cephalosporin, polymyxin, cefaclor, Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefinetazole, cefonioid, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil,. . .
16. The method according to claim 1, wherein the therapeutic agent further comprises **lysostaphin** for the treatment of any Staphylococcus aureus bacteria.

. . . agent which potentiates the bactericidal activity of the lysine enzyme, said complementary agent being selected from the group

consisting of **penicillin**, synthetic **penicillins** bacitracin, methicillin, cephalosporin, polymyxin, cefaclor, Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefmetazole, cefonioid, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil, . . .

36. The composition according to claim 22, wherein the therapeutic agent further comprises **lysostaphin** for the treatment of any Staphylococcus aureus bacteria.

L1 ANSWER 8 OF 10 USPATFULL on STN
AN 1999:4620 USPATFULL
TI Composition for treating mastitis and other staphylococcal infections
IN Blackburn, Peter, New York, NY, United States
Polak, June, Brooklyn, NY, United States
PA Ambi Inc., Tarrytown, NY, United States (U.S. corporation)
PI US 5858962 19990112
AI US 1993-168687 19931216 (8)
RLI Continuation of Ser. No. US 1989-440092, filed on 22 Nov 1989, now abandoned which is a continuation of Ser. No. US 1988-188183, filed on 28 Apr 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-48412, filed on 11 May 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Weddington, Kevin E.
LREP White & Case L.L.P.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:

1. A composition for killing staphylococci comprising **lysostaphin** and an agent which synergistically enhances the bactericidal activity of the **lysostaphin**, and which is in an amount effective to produce the synergistic enhancement, selected from the group consisting of **penicillin**, bacitracin, methicillin, cephalosporin and polymyxin and wherein the **lysostaphin** and the agent are together in amounts effective to kill staphylococci.

2. A composition for killing staphylococci comprising **lysostaphin** and at least one agent which synergistically enhances the bactericidal activity of the **lysostaphin**, and which is in an amount effective to produce the synergistic enhancement, selected from the group consisting of chelating agents and mild surfactants and wherein both the **lysostaphin** and the agent(s) are together in amounts effective to kill staphylococci.

. . . 3. A composition according to claim 1 which further comprises at least one agent which synergistically enhances bactericidal activity of **lysostaphin** selected from the group consisting of chelating agents and mild surfactants.

4. A composition according to claim 1, 2 or 3 wherein the **lysostaphin** is present at a concentration of at least 0.01 μg/ml.

5. A composition according to claim 1 or 3, containing **penicillin** in an amount effective to potentiate the killing effect of **lysostaphin**.

6. A composition according to claim 5, containing 0.1 μg/ml to 10.0 μg/ml **penicillin**.

7. A composition according to claim 2 or 3, containing a mild surfactant in an amount effective to potentiate the killing effect of the **lysostaphin**.

9. A composition according to claim 3, containing **penicillin**

an a mild surfactant in amounts effective to potentiate the killing effect of the **lysostaphin**.

11. A composition according to claim 10 containing 0.1 μg/ml to 10.0 μg/ml **penicillin**.

13. A composition according to claim 1, 2 or 3, wherein the **lysostaphin** is derived from a transformant microorganism containing a recombinant plasmid which codes for **lysostaphin**.

L1 ANSWER 9 OF 10 USPATFULL on STN
AN 1998:61641 USPATFULL
TI Method for treating mastitis and other staphylococcal infections
IN Blackburn, Peter, New York, NY, United States
Polak, June, Brooklyn, NY, United States
PA Ambi Inc., Tarrytown, NY, United States (U.S. corporation)
PI US 5760026 19980602
AI US 1994-303551 19940909 (8)
RLI Continuation of Ser. No. US 1992-935121, filed on 20 Aug 1992, now abandoned which is a continuation of Ser. No. US 1990-535286, filed on 8 Jun 1990, now abandoned which is a continuation of Ser. No. US 1988-188183, filed on 28 Apr 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-48412, filed on 11 May 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Weddington, Kevin E.
LREP White & Case L.L.P.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 844
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
1. A method of treating recurring staphylococcal mastitis resulting from intracellular Staphylococcus aureus comprising administering to an infected gland by intramammary infusion a therapeutic agent consisting essentially of the bacteriocin **lysostaphin** produced by recombinant means in a pharmaceutically acceptable carrier in an amount effective to eliminate the recurring staphylococcal mastitis.

2. A method according to claim 1, wherein from 2 mg to 400 mg of **lysostaphin** is administered to a bovine mammary gland.

. . . wherein the therapeutic agent further comprises a mild surfactant in an amount effective to potentiate the therapeutic effect of the **lysostaphin**.

. . . according to claim 1, wherein the therapeutic agent further comprises at least one agent which potentiates the bactericidal activity of **lysostaphin** selected from the group consisting of **penicillin**, synthetic **penicillins**, bacitracin, methicillin, cephalosporin, polymyxin and chelating agents in an amount effective to synergistically enhance the therapeutic effect of the **lysostaphin**.
5. A method according to claim 4, wherein the therapeutic agent further comprises a mild surfactant in an amount effective to potentiate the therapeutic effect of the **lysostaphin**.

L1 ANSWER 10 OF 10 USPATFULL on STN
AN 89:17168 USPATFULL
TI Antimicrobial fabrics utilizing graft copolymers
IN Calcaterra, Lidia T., Des Plaines, IL, United States
DeFilippi, Louis J., Mt. Prospect, IL, United States
Childs, Michael E., Medford, NJ, United States
Latos, Edwin J., Chicago, IL, United States

PA UOP, Des Plaines, IL, United States (U.S. corporation)
PI US 4810567 19890307
AI US 1987-94767 19870910 (7)
RLI Continuation-in-part of Ser. No. US 1985-768090, filed on 21 Aug 1985, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Bell, James J.
LREP McBride, Thomas K., Snyder, Eugene I.
CLMN Number of Claims: 19
ECL Exemplary Claim: 14
DRWN No Drawings
LN.CNT 945
CLM What is claimed is:

. . . of claim 1 where the antimicrobial is selected from the group consisting of the polymyxins, bacitracin, circulin, the octapeptins, lysozyme, **lysostaphin**, other cellulytic enzymes, vancomycin, ristocetin, the actinoidins, the avoparcins, tyrocidin A, gramicidin S, polyoxin D, tunicamycin, the polyene macrolide antibiotics, neomycin, streptomycin, and the **penicillins**.

. . . of claim 14 where the antimicrobial is selected from the group consisting of the polymyxins, bacitracin, circulin, the octapeptins, lysozyme, **lysostaphin**, other cellulytic enzymes, vancomycin, ristocetin, the actinoidins, the avoparcins, tryocidin A, gramicidin S, polyoxin D, tunicamycin, the polyene macrolide antibiotics, streptomycin, neomycin, and the **penicillins**.